

Transcatheter mitral valve implantation: a brief review

Darren Mylotte¹, MD; Nicolo Piazza^{2*}, MD

1. Department of Cardiology, Galway University Hospital, Galway, Ireland; 2. Division of Cardiology, McGill University Health Centre, Montreal, Quebec, Canada

KEYWORDS

- mitral regurgitation
- mitral valve
- transcatheter mitral valve implantation
- transcatheter mitral valve replacement

Abstract

In the last year transcatheter mitral valve implantation (TMVI) has seen a major jump in development. This technique offers the potential to treat a great number of elderly and/or high-risk patients with severe mitral regurgitation (MR). Such patients are declined surgical intervention either because the institutional Heart Team considers the risk of intervention to exceed the potential benefit, or because the patients and their families believe the morbidity of mitral surgery to be excessive. The advent of a less invasive transcatheter treatment could, therefore, potentially appeal to both clinicians and patients alike. In this overview paper, we describe briefly these recent developments in TVMI technologies as an introduction to the dedicated TVMI technical device parade later in this supplement.

*Corresponding author: Division of Cardiology/Interventional Cardiology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada. E-mail: nicolopiazza@mac.com

Finally! The past year has seen transcatheter mitral valve implantation (TMVI) begin in earnest. As the prevalence of mitral valve disease is almost three times that of aortic valve disease¹, this technique offers the potential to treat a great number of elderly and/or high-risk patients with severe mitral regurgitation (MR). Indeed, the Euro Heart Survey suggested that half of all patients hospitalised with symptomatic severe MR do not undergo potentially curative surgical repair/replacement due to advanced age, comorbid illnesses, and left ventricular dysfunction^{2,3}. More specifically, as few as 16% of patients with severe symptomatic functional MR and 53% of those with degenerative MR actually undergo surgery⁴. Furthermore, population-based data suggest that in the USA only 2% of eligible patients (MR \geq grade 3) undergo mitral valve surgery⁵⁻⁷. Such patients are declined surgical intervention either because the institutional Heart Team considers the risk of intervention to exceed the potential benefit⁸, or because the patients and their families believe the morbidity of mitral surgery to be excessive. The advent of a less invasive transcatheter treatment could, therefore, potentially appeal to both clinicians and patients alike.

Of course, there remains a great deal to learn about which patients could benefit from TMVI. Dr Elliot C. Cutler performed the first surgical mitral valve repair in 1923⁹, yet the mode of repair/replacement and the timing of the intervention still remain topics of some debate^{10,11}. As with transcatheter aortic valve implantation (TAVI), patient selection is determined by anatomical and clinical criteria. Both involve complex decision matrices which require much clarification. Anatomically, TMVI is a veritable minefield: a large, non-circular, saddle-shaped, highly dynamic, non-calcified annulus without the ability for radial anchoring which is tethered to a complex, highly individualised, subvalvular apparatus, and intimately related to the left ventricular outflow tract (LVOT), the coronary sinus, and the left circumflex coronary artery. Detailed multislice computed tomography analysis is imperative for patient selection and preoperative procedural

planning (**Figure 1**)¹². Clinically, while patient selection continues to evolve, there remain significant questions regarding the implications of large delivery sheath insertion in the left ventricle and the restoration of mitral valve competency in patients with very poor left ventricular function.

On June 12th, 2012, Lars Søndergaard and the Heart Team at Rigshospitalet in Copenhagen, Denmark, performed the first TMVI on an inoperable 86-year-old patient¹³. Using the first-generation CardiAQ valve system (CardiAQ Valve Technologies, Inc., Irvine, CA, USA), a successful transfemoral transeptal implantation was achieved with stable valve position and haemodynamics¹⁴. Although the patient succumbed to multi-organ failure on postoperative day three, TMVI feasibility had been demonstrated.

To date, five transcatheter mitral valve systems have been implanted in humans: CardiAQ valve system (CardiAQ Valve Technologies, Inc.); Tiara™ valve (Neovasc Inc., Richmond, Canada); FORTIS valve (Edwards Lifesciences, Irvine, CA, USA); Tendyne valve (Tendyne Inc., Roseville, MN, USA); and Twelve valve (Twelve, Inc., Redwood City, CA, USA). These devices share common features: nitinol self-expanding frames, trileaflet valves, bovine pericardial leaflets (Tendyne is porcine), fabric sealing skirt (CardiAQ is pericardial), and transapical delivery (CardiAQ also transeptal). Each of these systems, and those in preclinical development (Medtronic Mitral¹⁵ [Medtronic, Minneapolis MN, USA]; HighLife [HighLife Inc., Paris, France]), offer innovative design solutions to overcome the challenging anatomy of the mitral valve complex (**Figure 2**). TMVI systems must be flexible to deal with the complex and variable anatomy, provide large effective orifice areas, and deal with high transvalvular gradients (**Figure 3**). They must anchor without reliance on radial force (axial sealing), accommodate significant dislodgement forces, and avoid LVOT obstruction. Given these obstacles, additional areas of concern include stent fatigue and fracture, valve thrombosis, embolisation, leaflet durability, and paravalvular leak with resultant haemolysis.




Figure 1. Mitral valve CT analysis. Multislice computed tomography of the mitral valvular complex using the FluoroCT App.




Figure 2. Transcatheter mitral valve development timeline. *Tiara* (Neovasc Inc.); *FORTIS* (Edwards Lifesciences); *CardiAQ* (CardiAQ Valve Technologies, Inc.); *Tendyne* (Tendyne Inc.); *Twelve* (Twelve, Inc.).

On January 30th, 2014, Drs Anson Cheung and John Webb successfully implanted the first-in-human *Tiara* valve (Neovasc Inc.)¹⁶. The valve frame is asymmetric to fit the D-shaped mitral annulus. The 32 Fr transapical delivery catheter allows prosthesis recapture and repositionability, and the system anchors and seals using an atrial skirt and ventricular anchoring arms¹⁷. To date, four patients have been treated with successful device position and function in all cases. All patients were alive at 30 days.

In February and March 2014, Drs Martyn Thomas and Vinnie Bapat treated the first human patients with the *FORTIS* transcatheter valve (Edwards Lifesciences)¹⁸. The system is delivered via a 42 Fr sheathless delivery catheter, and anchors and seals using an atrial flange and symmetric paddles that clip the mitral leaflets on the ventricular side. Among 12 reported cases, successful delivery and valve function occurred in 11 cases, and 30-day mortality occurred in 25%. In May 2015, Edwards Lifesciences announced suspension of the *FORTIS* programme to investigate more thoroughly the presence of valve thrombosis.

On May 13th, 2015, almost two years after performing the first-in-human TMVI with the first-generation *CardiAQ* valve,

Lars Søndergaard and the Rigshospitalet Heart Team implanted the second-generation *CardiAQ* implant (CardiAQ Valve Technologies, Inc.), using a transapical delivery system. A month later, Francesco Romeo and Gian Paolo Ussia performed the first transfemoral transeptal implant of the second-generation device in Tor Vergata Hospital in Rome, Italy¹⁹. This system achieves sealing and anchoring using both left ventricular and left atrial anchors. Among eight treated patients, successful valve delivery and function was reported in seven cases. The 30-day mortality was 50%.

October 2014 witnessed the first human implants of the *Tendyne* valve (Tendyne Inc.) by Mr Neil Moat and the Heart Team at the Royal Brompton, London. The valve consists of a D-shaped frame that houses porcine pericardial leaflets. The prosthesis can be repositioned and is retrievable, and achieves sealing and anchoring by an atrial skirt and a left ventricular apical tether. Successful prosthesis delivery and function was achieved in all 12 patients treated. There were no 30-day deaths²⁰.

Therefore, as PCR London Valves moves east (temporarily) to Berlin from its spiritual home in London, another important transition is evident. Transcatheter heart valve technology has moved south from the aortic to the mitral valve, and TMVI has emerged as a clinical reality. Much work is required to iterate these devices and to optimise patient selection. This journey starts at PCR London Valves (Berlin) 2015.

Conflict of interest statement

D. Mylotte has no conflicts of interest to declare. N. Piazza is a member of the Scientific Advisory Board of Medtronic and a consultant and equity shareholder with HighLife.

References

1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. *Lancet*. 2006;368:1005-11.

TMVI design targets		Potential concerns	
Anchor & seal	Adaptable	Stent fatigue/fracture	Leaflet durability
User friendly	Durable	Valve dislodgement	PVL & haemolysis
Avoid interference	Reposition/recapture	LVOT obstruction	Large size matrix

Figure 3. TMVI design targets and potential concerns. LVOT: left ventricular outflow tract; PVL: paravalvular leak

2. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. *Eur Heart J*. 2003;24:1231-43.
3. Mirabel M, Iung B, Baron G, Messika-Zeitoun D, Détaint D, Vanoverschelde JL, Butchart EG, Ravaud P, Vahanian A. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? *Eur Heart J*. 2007;28:1358-65.
4. Bach DS, Awais M, Gurm HS, Kohnstamm S. Failure of guideline adherence for intervention in patients with severe mitral regurgitation. *J Am Coll Cardiol*. 2009;54:860-5.
5. Gammie JS, Sheng S, Griffith BP, Peterson ED, Rankin JS, O'Brien SM, Brown JM. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. *Ann Thorac Surg*. 2009;87:1431-7; discussion 1437-9.
6. Patel JB, Borgeson DD, Barnes ME, Rihal CS, Daly RC, Redfield MM. Mitral regurgitation in patients with advanced systolic heart failure. *J Card Fail*. 2004;10:285-91.
7. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS; 2006 Writing Committee Members; American College of Cardiology/American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. 2008;118:e523-661.
8. Andalib A, Mamane S, Schiller I, Zakem A, Mylotte D, Martucci G, Lauzier P, Alharbi W, Cecere R, Dorfmeister M, Lange R, Brophy J, Piazza N. A systematic review and meta-analysis of surgical outcomes following mitral valve surgery in octogenarians: implications for transcatheter mitral valve interventions. *EuroIntervention*. 2014;9:1225-34.
9. Cohn LH, Tchanchaleishvili V, Rajab TK. Evolution of the concept and practice of mitral valve repair. *Ann Cardiothorac Surg*. 2015;4:315-321.
10. Kang DH, Park SJ, Sun BJ, Cho EJ, Kim DH, Yun SC, Song JM, Park SW, Chung CH, Song JK, Lee JW, Park PW. Early surgery versus conventional treatment for asymptomatic severe mitral regurgitation: a propensity analysis. *J Am Coll Cardiol*. 2014;63:2398-407.
11. Acker MA, Parides MK, Perrault LP, Moskowitz AJ, Gelijs AC, Voisine P, Smith PK, Hung JW, Blackstone EH, Puskas JD, Argenziano M, Gammie JS, Mack M, Ascheim DD, Bagiella E, Moquete EG, Ferguson TB, Horvath KA, Geller NL, Miller MA, Woo YJ, D'Alessandro DA, Ailawadi G, Dagenais F, Gardner TJ, O'Gara PT, Michler RE, Kron IL. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. *N Engl J Med*. 2014;370:23-32.
12. Blanke P, Dvir D, Naoum C, Cheung A, Ye J, Thériault-Lauzier P, Spaziano M, Boone RH, Wood DA, Piazza N, Webb JG, Leipsic J. Prediction of fluoroscopic angulation and coronary sinus location by CT in the context of transcatheter mitral valve implantation. *J Cardiovasc Comput Tomogr*. 2015;9:183-92.
13. Søndergaard L, De Backer O, Franzen OW, Holme SJ, Ihlemann N, Vejlsstrup NG, Hansen PB, Quadri A. First-in-Human Case of Transfemoral CardiAQ Mitral Valve Implantation. *Circ Cardiovasc Interv*. 2015 Jul;8(7).
14. De Backer O, Piazza N, Banai S, Lutter G, Maisano F, Herrmann HC, Franzen OW, Søndergaard L. Percutaneous transcatheter mitral valve replacement: an overview of devices in preclinical and early clinical evaluation. *Circ Cardiovasc Interv*. 2014;7:400-9.
15. Piazza N, Bolling S, Moat N, Treede H. Medtronic transcatheter mitral valve replacement. *EuroIntervention*. 2014;10:U112-4.
16. Cheung A, Webb J, Verheye S, Moss R, Boone R, Leipsic J, Ree R, Banai S. Short-term results of transapical transcatheter mitral valve implantation for mitral regurgitation. *J Am Coll Cardiol*. 2014;64:1814-9.
17. Cheung A, Stub D, Moss R, Boone RH, Leipsic J, Verheye S, Banai S, Webb J. Transcatheter mitral valve implantation with Tiara bioprosthesis. *EuroIntervention*. 2014;10:U115-9.
18. Bapat V, Buellesfeld L, Peterson MD, Hancock J, Reineke D, Buller C, Carrel T, Praz F, Rajani R, Fam N, Kim H, Redwood S, Young C, Munns C, Windecker S, Thomas M. Transcatheter mitral valve implantation (TMVI) using the Edwards FORTIS device. *EuroIntervention*. 2014;10:U120-8.
19. Ussia GP, Quadri A, Cammalleri V, De Vico P, Muscoli S, Marchei M, Ruvolo G, Søndergaard L, Romeo F. Percutaneous transfemoral-transseptal implantation of second-generation CardiAQ™ mitral valve bioprosthesis: first procedure description and 30-day follow-up. *EuroIntervention*. 2015 Sep 5 [Epub ahead of print].
20. Moat N, Duncan A, Lindsay A, Quarto C, Blanke P, Leipsic J, Grayburn P, Davies S. Transcatheter mitral valve replacement for the treatment of mitral regurgitation: in-hospital outcomes of an apically tethered device. *J Am Coll Cardiol*. 2015;65:2352-3.